Latest Headlines

  1. Organs Age At Different Speeds: A Blood Test Might Soon Tell Which Ones 8/14/2026

    AI-based “tissue clocks” can estimate the biological age of human organs from histological images, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Ludwig Boltzmann Institute for Network Medicine (LBI-NetMed) at the University of Vienna showed. By analyzing more than 25,000 tissue samples across 40 tissue types, their study reveals that organs age at different rates throughout life and that these changes can even be detected from blood samples.

  2. Lam Research Announces Plans To Invest More Than $3B To Expand Global Lab Network, Increase Innovation Velocity In The AI Era 8/13/2026

    Lam Research Corp. (NASDAQ: LRCX) today announced that it intends to invest more than $3 billion over the next five years to expand its global research and development (R&D) lab network.

  3. biomodal Launches Duet Mosaic Giving Liquid Biopsy Researchers And Developers More Signal From Every Blood Draw 8/12/2026

    biomodal, an omics-based life sciences technology and analytics company, today announced the launch of the duet mosaic family, which includes two new circulating cell-free DNA (cfDNA)-optimized multiomic sequencing workflows for liquid biopsy and translational research.

  4. Vivodyne Launches The World's Largest Human Biological Datacenter To Train The First World Model Of Human Biology 8/12/2026

    Vivodyne, the company making human biology computable at AI scale, today announced the world’s largest human biological datacenter, with 12 robotic HIVE laboratories and the annual capacity to perform controlled trials on 3.1 million large human tissues per year — estimated at twice the scale of every clinical trial in the USA combined.

  5. Amprion Partners With MLM Medical Labs To Expand Alpha-Synuclein SAA Testing In Europe 8/12/2026

    Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a strategic licensing collaboration with MLM Medical Labs, a global central and specialty laboratory with operations in Germany.

  6. Ultra Sensitive Multiplex Biomarker Detection Kits 8/12/2026

    Utilising enzyme-free DNA nanotechnology, immunoMUSE kits from Amsbio enable researchers to perform ultra-sensitive, 2-plex to 4-plex custom biomarker detection in tissue while generating same-day imaging results without species or isotype constraints.

  7. NIAID Awards Zepto Life Technology Contract Valued At Up To $8.9M To Advance The First Deployable Liquid Biopsy Platform For Infectious Disease 8/11/2026

    Zepto Life Technology today announced that it has been awarded a contract valued at up to $8.9 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance its plasma cell-free DNA liquid biopsy platform for invasive fungal infections.

  8. Leica Biosystems Enables Faster Cancer Diagnoses Through Multiple Digital Pathology FDA Clearances, Including Industry-First AI-Assisted Quality Control Software 8/11/2026

    Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced multiple U.S. Food and Drug Administration (FDA) 510(k) clearances that strengthen its connected clinical digital pathology portfolio, including the industry's first standalone, AI-assisted quality control software.

  9. A Blood Test Can Provide More Information About Cancer 8/11/2026

    A single blood test could in future provide a more comprehensive picture of cancer than current methods. In a review article published in the journal Genome Medicine, researchers at Karolinska Institutet describe how several different biological signals can be analysed simultaneously from the same blood sample to detect and monitor cancer diseases.

  10. Bruker Announces Strategic Collaboration With Atinary Technologies To Advance Self-Driving Laboratories 8/11/2026

    Bruker Corporation today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary.